To sell PST periodontal disease genetic test in New York

Interleukin Genetics has received approval from the state of New York’s Department of Health, to sell in New York its PST genetic test that determines predisposition to severe periodontal disease in individuals.

The test is available in all other states in the US. However, through its clinical laboratory evaluation program (CLEP), New York monitors the accuracy and reliability of results of laboratory tests, including genetic tests, on specimens obtained within the state.

Interleukin Genetics currently distributes its PST genetic test to dentists through a licensing agreement with OralDNA Labs, a subsidiary of Quest Diagnostics. This approval will further expand OralDNA Labs’ reach to the dentist community with the PST test.

The PST genetic test provides a means of assessing an individual’s genetic risk for periodontal disease, the most common cause of tooth loss. PST is the genetic test available that is capable of identifying which patients are at increased risk for developing severe periodontal disease and can provide dentists and hygienists with important clinical information about their patients.

The test is useful in patients with early signs of periodontal disease, including recurrent gingivitis and early-to-moderate periodontitis to identify patients more likely to develop severe periodontitis and associated complications.

Lewis Bender, CEO of Interleukin Genetics, said: “We are pleased to have met New York’s standard for both our laboratory practices and our PST test. This approval by New York further supports our commitment to provide genetic tests that offer strong clinical value. PST along with our Heart Health now both meet New York State’s unique criteria.”